Fagerstrom Test for Nicotine Dependence

The Fagerstrom Test for Nicotine Dependence (FTND) is the most widely used standardized instrument for assessing the intensity of physical dependence on nicotine. Originally developed by Karl-Olov Fagerstrom in 1978 as the Fagerstrom Tolerance Questionnaire (FTQ) and subsequently revised by Heatherton et al. in 1991, the FTND has become an essential clinical tool for guiding smoking cessation treatment planning and predicting cessation outcomes.

Tobacco use remains the leading preventable cause of death worldwide, responsible for more than 8 million deaths annually according to the World Health Organization. Approximately 1.3 billion people worldwide use tobacco products, and nicotine dependence is classified as a substance use disorder in the DSM-5. The severity of nicotine dependence is a critical factor in determining appropriate cessation strategies, pharmacotherapy selection, and likelihood of successful quit attempts.

The FTND consists of six items that assess key indicators of physical nicotine dependence. Two items are scored on a 4-point scale (0-3): time to first cigarette after waking and number of cigarettes smoked per day. Four items are scored dichotomously (0-1): difficulty refraining from smoking in forbidden places, which cigarette is hardest to give up, smoking more in the morning, and smoking while ill. The total score ranges from 0 to 10.

Research has consistently demonstrated that the FTND score correlates with biochemical markers of tobacco exposure, including cotinine levels, exhaled carbon monoxide, and carboxyhemoglobin concentrations. Higher FTND scores predict greater difficulty in achieving cessation, higher withdrawal symptom severity, and increased likelihood of relapse. The time-to-first-cigarette item alone has been shown to be a particularly powerful predictor of dependence severity.

Clinical application of the FTND extends beyond simple risk stratification. The score directly informs pharmacotherapy decisions in smoking cessation. Patients with moderate to high dependence (FTND 4-10) typically benefit from combination pharmacotherapy, such as nicotine replacement therapy (NRT) combined with varenicline or bupropion. Those with very high dependence (FTND 7-10) may require higher-dose NRT or pre-cessation NRT to manage withdrawal symptoms effectively.

The FTND has been translated into numerous languages and validated across diverse cultural contexts. Meta-analyses of its psychometric properties report adequate internal consistency (Cronbach's alpha 0.56-0.64) and good test-retest reliability. While some researchers have noted that the modest alpha values reflect the multidimensional nature of nicotine dependence rather than poor scale quality, the FTND remains the gold standard for clinical assessment of physical nicotine dependence.

Limitations of the FTND include its focus on physical dependence aspects of cigarette smoking, potentially underrepresenting psychological and behavioral dimensions of tobacco dependence. It was designed specifically for cigarette smokers and may not directly apply to users of other tobacco or nicotine products such as e-cigarettes, smokeless tobacco, or heated tobacco products. Despite these limitations, the FTND provides invaluable clinical information for personalizing cessation treatment approaches.

This calculator implements the standard FTND scoring algorithm, providing both the total score and an interpretation of dependence severity level to guide clinical decision-making in smoking cessation management.